期刊文献+

早期他汀类干预对不稳定性冠状动脉疾病患者血清C反应蛋白水平的影响 被引量:4

Effect of early cholesterol-reducing on the serum level of high sensitive C-reactive protein in unstable coronary artery disease
原文传递
导出
摘要 目的观察早期调脂干预对不稳定性冠状动脉疾病患者血清高敏C反应蛋白(hsCRP)的影响。方法50例连续入院的不稳定性冠状动脉疾病患者随机分为调脂治疗组和对照组,每组25例。治疗组在入院后予辛伐他汀20 mg夜间顿服,对照组未予调脂治疗。于入院时、入院后5 d(调脂治疗3 d)、12 d(调脂治疗10 d)测定血清hsCRP水平,并比较两组心绞痛发生次数及心绞痛累计时间。结果入院24 h、入院5 d和12 d治疗组hsCRP分别为(6.96±1.93)mg/L、(4.21±2.18)mg/L、(3.81±1.66)mg/L,组内比较差异有统计学意义(P<0.05);对照组分别为(7.44±6.52)mg/L、(5.32±3.48)mg/L、(4.98±1.74)mg/L,组内比较差异无统计学意义(P>0.05)。入院时hsCRP两组间差异无统计学意义,入院12 d调脂治疗组hsCRP显著低于对照组(P<0.05)。两组心绞痛次数及心绞痛累计时间差异无统计学意义。结论早期调脂干预可以降低不稳定性冠状动脉疾病急性期hsCRP水平。 Objective To observe the effect of early cholesterol-reducing on the serum level of high sensitive C-reactive(hsCRP) in unstable coronary artery disease. Methods Fifty consecutive patients with unstable coronary artery disease were randomized into cholesterol-reducing group and control group (n = 25). Cholesterol-reducing group were treated with simvastatin 20mg qn. hsCRP was assayed on the 1st, 5th and 12th day after admission. Angina frequency and cumulative angina time were documented. Results The serum level of hsCRP in the simvastatin group on the lst,5th and 12th day after admission was (6.96 ± 1.93)mg/L, (4.21 ± 2.18)mg/L, (3.81 ± 1.66)mg/L,respectively(P〈 0.05),however it was (7.44±6.52) mg/L, (5.32 ± 3.48)mg/L, (4.98±1.74) mg/L respectively in the control group(P 〉 0.05). The serum level of hsCRP in the simavastatin group on 12th day after admission was significantly lower than that in the control group( P 〈 0.05). There were no differences in angina frequency and cumulative angina time between the two groups. Conclusion Early cholesterol reducing can decrease hsCRP in unstable coronary artery disease.
出处 《中国基层医药》 CAS 2007年第4期551-552,共2页 Chinese Journal of Primary Medicine and Pharmacy
关键词 冠状动脉疾病 炎性反应 他汀类药物 C反应蛋白 Coronary disease Inflammation Statins C- reactive protein
  • 相关文献

参考文献8

二级参考文献44

  • 1[1]Ross R. Atherosclercsis: an inflammatory disease.disease. N Engl J Med, 1999,340:115-126
  • 2[2]PasceriV, Willerson JT, Yeh ETH. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation, 2000, 102:2 165-168
  • 3[3]Pasceri V, Chang J, Willerson JT, etal. Modulation of C-reactiveprotein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclemsis drugs. Circulation, 2001. 103:2 531-534
  • 4[4]Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages implications for atherosclerosis. Circulation,2001, 103: 1194-197
  • 5[5]Bhakdi S, Torzewski M, Klouche M, et al. Complement and athemgenesis:binding of CRP to degraded, nonoxidized LDL enhances complement activation.Arterisocler Thromb Vasc Biol, 1999, 19:2 348-354
  • 6[6]Griselli BM, Herbert J, Hutchirnson WL, et al. C-eractive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med, 1999, 190: 1733-739
  • 7[7]Zhang YX, Cliff WJ, Schoefl GI, et al. Coronary C-reactive protein distribution: its relation to development of atherosclerosis. Atherosclerosis, 1999, 145:375-379
  • 8[8]HeinrichJ, Suchute H, Schonfeld R, et al. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thrornb Haemostas, 1995, 73:374-378
  • 9[9]Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein (a), and standard cholesterol screening as predictors of preipheral arterial diseaes. JAMA, 2001, 285:24 814-815
  • 10[10]Tataru MC, Heinrich J, Junker R, et al. C-reactive protein and the severity of atherosclerosic in myocardial infaction patients with stable angina pertoris. Eur heart J, 2000, 21:1000

共引文献98

同被引文献15

  • 1Smith A,秦春常.哪些凝血标志物可以增加传统危险因素对冠心病和缺血性中风的预测价值?Caerphilly研究[J].中国分子心脏病学杂志,2005,5(6):821-821. 被引量:43
  • 2无.慢性稳定性心绞痛诊断与治疗指南[J].中华心血管病杂志,2007,35(3):195-206. 被引量:2120
  • 3Sakayama K, Masuno H, Okumura H, et al. Recombinant human tumor necrosis factor - alpha suppress synthesis, activity and secretion of lipoprotein lipase in cultures of a human osteosarcoma cell line [J]. Biochem J, 1996, 316 (3): 813-817.
  • 4Jenny NS, Tracy RP, Ogg MS, et al. In the eldely, interleukin -6 plasma levels and the polymorphism are associated with the development of cardiovascular disease [ J ]. Arterioscler Thromb vase Boil, 2002, 22 (12): 2066-2071.
  • 5Mizia SK, Gasior Z, Markiewicz BZ, et al. Serum tumor necrosis factor alpha, interleukin -2 and interleukin - 10 activation in stable angina and acute coronary syndromes [J]. Coronary Artery Disease, 2003, 14 (6): 431-438.
  • 6Koch W, Kastrati A, Botiger C, et al. Interleukin - 10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial in farction [J]. Atherosclerosis, 2001, 159 (10) : 137 - 144.
  • 7Ridker PM, Rifai N, Stampfer M J, et al. Plasma concentration of interleukin - 6 and the risk of future myocardial infarction among apparently healthy men [J]. Circulation, 2000, 101 (15) : 1767 -1772.
  • 8Heeschen C, Dimmeler S, Human CW, et al. CAPTURE Study Investigators Serum level of the anti - inflammatory cytokine interleukin - 10 is an important prognostic determinant in patients with acute coronary syndromes [J]. Circulation, 2003, 107 (16): 2109-2114.
  • 9Sullivan DR, Marwick TH, Freedman SB. A new method of scoring coro- nary angiograms to reflect extent of coronary atheroselerosis and improve correlation with major risk factors[ J ]. Am Heart J, 1990, 119 ( 6 ) : 1262 - 1267.
  • 10Ridker PM, Rifai N, Pfeffer M, et al. Elevation of tumor necrosis factor- alpha and increase risk if recerrent coronary events after myocardial in- farction[ J ]. Circulation,2000,101 ( 18 ) :2149 - 2153.

引证文献4

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部